According to epidemiologist Dr. Katelyn Jetelina, the United States could be experiencing its most significant disruption to vaccine policy in 70 years, with anti-vaccine advocates now controlling federal vaccine recommendations for 330 million Americans. This assessment comes from Dr. Jetelina,
The COVID-19 pandemic fundamentally changed pharmaceutical manufacturing approaches – demonstrating it’s possible to dramatically compress traditional timelines while maintaining quality standards. At CDMO Live 2025, Fabrice Le Garrec, founder of the OSICS network, shared lessons learned from his experience during
“When you’re building something at the edge of science, it’s crucial to start with the problem, not the solution. My team has created 15 pharma startups using this approach, and 14 are still alive.” – Kerstin Papenfuss, Director of Pharma
The escalating military conflict between Israel and Iran has reached a critical juncture, with Iran’s parliament voting to close the Strait of Hormuz in response to U.S. military actions on 22nd June 2025. This potential closure of the world’s most
“This enterprise is lacking congressional support. The host of prior leaders in this policy space have left,” warn biodefense advocates pushing for renewed bipartisan commitment Jennifer Alton, President of Pathway Policy Group, delivered this stark assessment during a biodefense policy
At CDMO Live 2025, a panel sponsored by Lifecore Biomedical brought together industry quality leaders to discuss how quality management can become a strategic enabler rather than a compliance burden. The panel featured Jackie Klecker (EVP Quality & Development Services,
“Risk is always a function of volatility. And I think everyone agrees that volatility in markets, also in the pharmaceutical industry with regards to tariffs, has actually increased,” explains David Schneider, CEO of Qualifyze, discussing the evolving landscape of supplier
“We invest to meet the needs of the customer. What’s driving these investments are really the customer partnerships that we’re building to make these happen,” explains Arul Ramadurai, Chief Commercial Officer at Axplora. Axplora, a global leader in API small
National Resilience, the contract development and manufacturing organisation (CDMO) that has raised over $2 billion since its 2020 founding, announced Monday it would “wind down” facilities whilst securing $250 million in bridge financing from existing investors. The company’s restructuring involves
At CDMO Live 2025, a panel of digital manufacturing experts explored how pharma companies are transforming external manufacturing operations through digital integration. Sponsored by Aizon. The Digital Divide: Big Pharma vs Mid-Size Players The panellists painted a stark contrast in
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
